uric acid has been researched along with Intestinal Diseases in 12 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Intestinal Diseases: Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The results showed that MFPP could effectively reduce the serum uric acid (SUA) levels compared with the model group rats; kidney histopathology and the levels of inflammatory factors (TNF-α, IL-6, and IL-10) indicated that MFPP attenuated HUA-induced kidney inflammation." | 8.31 | Marine Fish Protein Peptide Regulating Potassium Oxonate-Induced Intestinal Dysfunction in Hyperuricemia Rats Helps Alleviate Kidney Inflammation. ( Hu, Q; Luo, J; Peng, X; Wu, C; Zhang, G, 2023) |
| " The results showed that MFPP could effectively reduce the serum uric acid (SUA) levels compared with the model group rats; kidney histopathology and the levels of inflammatory factors (TNF-α, IL-6, and IL-10) indicated that MFPP attenuated HUA-induced kidney inflammation." | 4.31 | Marine Fish Protein Peptide Regulating Potassium Oxonate-Induced Intestinal Dysfunction in Hyperuricemia Rats Helps Alleviate Kidney Inflammation. ( Hu, Q; Luo, J; Peng, X; Wu, C; Zhang, G, 2023) |
| "Urinary stones are much more common in subjects with intestinal diseases than in the general population." | 2.36 | [Urinary lithiasis secondary to intestinal diseases]. ( Calmus, Y; Gendre, JP; Mignon, F, 1983) |
| "Uric acid (UA) has anti- and pro-inflammatory properties." | 1.72 | Protective Effect of Luminal Uric Acid Against Indomethacin-Induced Enteropathy: Role of Antioxidant Effect and Gut Microbiota. ( Akiyama, M; Hanawa, Y; Higashiyama, M; Hokari, R; Horiuchi, K; Inaba, K; Ito, S; Komoto, S; Kurihara, C; Mizoguchi, A; Nishii, S; Okada, Y; Shibuya, N; Sugihara, N; Takei, F; Tanemoto, R; Tomita, K; Wada, A; Watanabe, C, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (75.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, C | 1 |
| Hu, Q | 1 |
| Peng, X | 1 |
| Luo, J | 1 |
| Zhang, G | 1 |
| Wada, A | 1 |
| Higashiyama, M | 1 |
| Kurihara, C | 1 |
| Ito, S | 1 |
| Tanemoto, R | 1 |
| Mizoguchi, A | 1 |
| Nishii, S | 1 |
| Inaba, K | 1 |
| Sugihara, N | 1 |
| Hanawa, Y | 1 |
| Horiuchi, K | 1 |
| Shibuya, N | 1 |
| Akiyama, M | 1 |
| Okada, Y | 1 |
| Watanabe, C | 1 |
| Komoto, S | 1 |
| Tomita, K | 1 |
| Takei, F | 1 |
| Hokari, R | 1 |
| Fantozzi, ET | 1 |
| Breithaupt-Faloppa, AC | 1 |
| Ricardo-da-Silva, FY | 1 |
| Rodrigues-Garbin, S | 1 |
| Romero, DC | 1 |
| da Silva Rodrigues, A | 1 |
| Riffo-Vasquez, Y | 1 |
| Tavares-de-Lima, W | 1 |
| Calmus, Y | 1 |
| Gendre, JP | 1 |
| Mignon, F | 1 |
| Malek, RS | 1 |
| Wilson, DM | 1 |
| Bissada, NK | 1 |
| Redman, JF | 1 |
| Holzmann, H | 1 |
| Hoede, N | 1 |
| Morsches, B | 1 |
| Gelzayd, EA | 1 |
| Breuer, RI | 1 |
| Kirsner, JB | 1 |
| Smith, LH | 2 |
| Eickhorn, C | 1 |
2 reviews available for uric acid and Intestinal Diseases
| Article | Year |
|---|---|
[Urinary lithiasis secondary to intestinal diseases].
Topics: Humans; Intestinal Diseases; Oxalates; Uric Acid; Urinary Calculi | 1983 |
Renal lithiasis: a practical approach.
Topics: Acidosis, Renal Tubular; Adult; Child, Preschool; Cystinuria; Female; Humans; Hypercalcemia; Intesti | 1977 |
10 other studies available for uric acid and Intestinal Diseases
| Article | Year |
|---|---|
Marine Fish Protein Peptide Regulating Potassium Oxonate-Induced Intestinal Dysfunction in Hyperuricemia Rats Helps Alleviate Kidney Inflammation.
Topics: Animals; Carrier Proteins; Fish Proteins; Hyperuricemia; Inflammation; Intestinal Diseases; Kidney; | 2023 |
Protective Effect of Luminal Uric Acid Against Indomethacin-Induced Enteropathy: Role of Antioxidant Effect and Gut Microbiota.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Disease Models, Animal; Fecal Microb | 2022 |
Estradiol mediates the long-lasting lung inflammation induced by intestinal ischemia and reperfusion.
Topics: Animals; Cytokines; Estradiol; Female; Intestinal Diseases; Intestines; Leukocyte Count; Lung; Lung | 2018 |
Medical treatment of urolithiasis.
Topics: Acidosis, Renal Tubular; Aged; Calcium; Calcium, Dietary; Cystinuria; Diet; Humans; Intestinal Disea | 1979 |
Medical management of urolithiasis.
Topics: Anti-Bacterial Agents; Calcium; Cystinuria; Diarrhea; Female; Humans; Hydrochlorothiazide; Intestina | 1976 |
[Organ findings in psoriasis].
Topics: Dehydroepiandrosterone; Erythrocytes; Female; Gout; Humans; Intestinal Diseases; Joint Diseases; Liv | 1973 |
Nephrolithiasis in inflammatory bowel disease.
Topics: Adrenocorticotropic Hormone; Adult; Calcium; Colitis, Ulcerative; Crohn Disease; Female; Humans; Ile | 1968 |
The diagnosis and treatment of metabolic stone disease.
Topics: Acidosis, Renal Tubular; Age Factors; Calcium; Cystinuria; Humans; Hypercalcemia; Intestinal Disease | 1972 |
Nephrolithiasis. Current concepts in pathogenesis and management.
Topics: Acidosis, Renal Tubular; Citrates; Cystinuria; Humans; Hydrochlorothiazide; Hydrogen-Ion Concentrati | 1972 |
[Urate calculi and urate kidney treatment from the viewpoint of hepato-intestinal dysfunction in uric acid].
Topics: Disease Susceptibility; Female; Humans; Intestinal Diseases; Kidney Calculi; Liver Diseases; Male; M | 1970 |